A Clinical Comparative study to evaluate the safety and efficacy of Himfera capsules in the Management of Iron Deficiency Anaemia - HimC

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subjects of both sexes in the age group of 18-70 years with Hemoglobin <11gm/dL.
•2.Subjects who have clinical symptoms such as pale skin colour, extreme fatigue, irritability, weakness, brittle nails, palpitation, headache, loss of appetite.
•3.Subjective improvement in quality of life in subjects with Iron deficiency anaemic.
•4.Subjects willing to give written informed consent.
•5.Subjects who have not participated in similar kind of study in last 3 months.

•Subjects with hemoglobin concentration < 6 gm/dl, patients of thalassaemia, sickle cell anemia, aplastic anemia, haemolytic anemia, lead poisoning, sideroblastic anaemia, malignancies, congenital.
•Blood hemoglobin level < 5 gm/dl during the course of any treatment, any other acute illness, severe untoward effect.
•Absence of iron binding protein, hereditory spherocytosis and any association of severe complication.
•Pregnant & lactating women.
•Not willing to sign informed consent form.

发起方